OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Effect of tenofovir alafenamide vs. tenofovir disoproxil fumarate on hepatocellular carcinoma risk in chronic hepatitis B
Hye Won Lee, Young Youn Cho, Hyein Lee, et al.
Journal of Viral Hepatitis (2021) Vol. 28, Iss. 11, pp. 1570-1578
Closed Access | Times Cited: 19
Hye Won Lee, Young Youn Cho, Hyein Lee, et al.
Journal of Viral Hepatitis (2021) Vol. 28, Iss. 11, pp. 1570-1578
Closed Access | Times Cited: 19
Showing 19 citing articles:
2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma
Clinical and Molecular Hepatology (2022) Vol. 28, Iss. 4, pp. 583-705
Open Access | Times Cited: 189
Clinical and Molecular Hepatology (2022) Vol. 28, Iss. 4, pp. 583-705
Open Access | Times Cited: 189
2022 KLCA-NCC Korea Practice Guidelines for the Management of Hepatocellular Carcinoma
Korean Journal of Radiology (2022) Vol. 23, Iss. 12, pp. 1126-1126
Open Access | Times Cited: 88
Korean Journal of Radiology (2022) Vol. 23, Iss. 12, pp. 1126-1126
Open Access | Times Cited: 88
2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma
Journal of Liver Cancer (2022) Vol. 23, Iss. 1, pp. 1-120
Open Access | Times Cited: 80
Journal of Liver Cancer (2022) Vol. 23, Iss. 1, pp. 1-120
Open Access | Times Cited: 80
Development of hepatocellular carcinoma in treated and untreated patients with chronic hepatitis B virus infection
Chih‐Lin Lin, Jia‐Horng Kao
Clinical and Molecular Hepatology (2023) Vol. 29, Iss. 3, pp. 605-622
Open Access | Times Cited: 36
Chih‐Lin Lin, Jia‐Horng Kao
Clinical and Molecular Hepatology (2023) Vol. 29, Iss. 3, pp. 605-622
Open Access | Times Cited: 36
Efficacy and safety of tenofovir alafenamide versus tenofovir disoproxil fumarate in treatment‐naïve chronic hepatitis B
Jihye Lim, Won‐Mook Choi, Ju Hyun Shim, et al.
Liver International (2022) Vol. 42, Iss. 7, pp. 1517-1527
Closed Access | Times Cited: 28
Jihye Lim, Won‐Mook Choi, Ju Hyun Shim, et al.
Liver International (2022) Vol. 42, Iss. 7, pp. 1517-1527
Closed Access | Times Cited: 28
Observational pilot study of switching from entecavir to tenofovir alafenamide in patients with chronic hepatitis B
Takuya Matsubara, Satoru Hagiwara, Naoshi Nishida, et al.
Scientific Reports (2025) Vol. 15, Iss. 1
Open Access
Takuya Matsubara, Satoru Hagiwara, Naoshi Nishida, et al.
Scientific Reports (2025) Vol. 15, Iss. 1
Open Access
Comparison of hepatocellular carcinoma incidence after long-term treatment with besifovir vs. tenofovir AF
Hyuk Kim, Jaeyoung Kim, Yoon E Shin, et al.
Scientific Reports (2025) Vol. 15, Iss. 1
Open Access
Hyuk Kim, Jaeyoung Kim, Yoon E Shin, et al.
Scientific Reports (2025) Vol. 15, Iss. 1
Open Access
Noninferiority Outcomes of Besifovir Compared to Tenofovir Alafenamide in Treatment-Naïve Patients with Chronic Hepatitis B
Tae Hyung Kim, Ji Hoon Kim, Hyung Joon Yim, et al.
Gut and Liver (2024) Vol. 18, Iss. 2, pp. 305-315
Open Access | Times Cited: 2
Tae Hyung Kim, Ji Hoon Kim, Hyung Joon Yim, et al.
Gut and Liver (2024) Vol. 18, Iss. 2, pp. 305-315
Open Access | Times Cited: 2
On-treatment risks of cirrhosis and hepatocellular carcinoma among a large cohort of predominantly non-Asian patients with non-cirrhotic chronic hepatitis B
Zeyuan Yang, Ramsey Cheung, Amit S. Chitnis, et al.
JHEP Reports (2023) Vol. 5, Iss. 10, pp. 100852-100852
Open Access | Times Cited: 6
Zeyuan Yang, Ramsey Cheung, Amit S. Chitnis, et al.
JHEP Reports (2023) Vol. 5, Iss. 10, pp. 100852-100852
Open Access | Times Cited: 6
Hepatitis B Before and After Hepatocellular Carcinoma
Murat Harputluoğlu, Brian I. Carr
Journal of Gastrointestinal Cancer (2021) Vol. 52, Iss. 4, pp. 1206-1210
Closed Access | Times Cited: 14
Murat Harputluoğlu, Brian I. Carr
Journal of Gastrointestinal Cancer (2021) Vol. 52, Iss. 4, pp. 1206-1210
Closed Access | Times Cited: 14
Are the New Nucleos(t)ide Analogs Better than the Old Nucleos(t)ide Analogs?
Jonggi Choi, Won‐Mook Choi, Young‐Suk Lim
Clinics in Liver Disease (2023) Vol. 27, Iss. 4, pp. 809-818
Closed Access | Times Cited: 2
Jonggi Choi, Won‐Mook Choi, Young‐Suk Lim
Clinics in Liver Disease (2023) Vol. 27, Iss. 4, pp. 809-818
Closed Access | Times Cited: 2
Risk of hepatocellular carcinoma after curative treatment when switching from tenofovir disoproxil fumarate or entecavir to tenofovir alafenamide: A real‐world multicenter cohort study
Hyun‐Jae Shin, Seung Up Kim, Byeong Geun Song, et al.
Hepatology Research (2024) Vol. 54, Iss. 7, pp. 627-637
Closed Access
Hyun‐Jae Shin, Seung Up Kim, Byeong Geun Song, et al.
Hepatology Research (2024) Vol. 54, Iss. 7, pp. 627-637
Closed Access
Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in virologically suppressed patient with chronic hepatitis B
Heechul Nam, Ji Won Han, Soon Kyu Lee, et al.
Journal of Gastroenterology and Hepatology (2024) Vol. 39, Iss. 8, pp. 1673-1683
Open Access
Heechul Nam, Ji Won Han, Soon Kyu Lee, et al.
Journal of Gastroenterology and Hepatology (2024) Vol. 39, Iss. 8, pp. 1673-1683
Open Access
Examination of the long-term efficacy and safety of switching from entecavir to tenofovir alafenamide, including the anti-carcinogenic effect
Takuya Matsubara, Satoru Hagiwara, Naoshi Nishida, et al.
Research Square (Research Square) (2024)
Closed Access
Takuya Matsubara, Satoru Hagiwara, Naoshi Nishida, et al.
Research Square (Research Square) (2024)
Closed Access
Validation of PH and Varices Risk Scores for Prediction of High-Risk Esophageal Varix and Bleeding in Patients with B-Viral Cirrhosis
Seung-Hwan Shin, Seung Up Kim, Jun Yong Park, et al.
Diagnostics (2022) Vol. 12, Iss. 2, pp. 441-441
Open Access | Times Cited: 2
Seung-Hwan Shin, Seung Up Kim, Jun Yong Park, et al.
Diagnostics (2022) Vol. 12, Iss. 2, pp. 441-441
Open Access | Times Cited: 2
Risk of HCC in Patients with HBV, Role of Antiviral Treatment
Terry Cheuk‐Fung Yip, Jimmy Che‐To Lai, Lilian Yan Liang, et al.
Current Hepatology Reports (2022) Vol. 21, Iss. 4, pp. 76-86
Closed Access | Times Cited: 2
Terry Cheuk‐Fung Yip, Jimmy Che‐To Lai, Lilian Yan Liang, et al.
Current Hepatology Reports (2022) Vol. 21, Iss. 4, pp. 76-86
Closed Access | Times Cited: 2
Tenofovir disoproxil fumarate is superior to Entecavir and Tenofovir alafenamide in Cost-Effectiveness of Treatment of Chronic Hepatitis B in China with New Volume-Based Purchasing Policy
Yi Lin, Xueyan Lin, Juan Chen, et al.
Research Square (Research Square) (2023)
Open Access
Yi Lin, Xueyan Lin, Juan Chen, et al.
Research Square (Research Square) (2023)
Open Access
Cost-Effectiveness of First-Line Nucleos(T)Ide Analogs for Treatment of Chronic Hepatitis B in China with New Volume-Based Purchasing Policy
Xueyan Lin, Yi Lin, Zhihui Lin, et al.
SSRN Electronic Journal (2022)
Closed Access
Xueyan Lin, Yi Lin, Zhihui Lin, et al.
SSRN Electronic Journal (2022)
Closed Access
